4.7 Article

Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT

Journal

Publisher

SPRINGER
DOI: 10.1007/s00259-021-05670-z

Keywords

Immuno-SPECT/CT; EpCAM imaging; [Tc-99m]Tc-Nanobody; Site-specific radiolabeling

Funding

  1. National Natural Science Foundation of China (NSFC) [81871416, 81630045, 81927802, 81621063]
  2. National Key R&D Program of China [2017YFA0205600]

Ask authors/readers for more resources

In this study, a site-specifically labeled EpCAM-targeted nanobody was synthesized and evaluated for the noninvasive imaging of EpCAM expression using SPECT/CT. The results showed high EpCAM specificity and the potential for clinical translation.
Purpose Overexpression of epithelial cell adhesion molecule (EpCAM) plays essential roles in tumorigenesis and tumor progression in almost all epithelium-derived cancer. Monitoring EpCAM expression in tumors can be used for the diagnosis, staging, and prognosis of cancer patients, as well as guiding the individualized treatment of EpCAM-targeted drugs. In this study, we described the synthesis and evaluation of a site-specifically [Tc-99m]Tc-labeled EpCAM-targeted nanobody for the SPECT/CT imaging of EpCAM expression. Methods We first prepared the [Tc-99m]Tc-HYNIC-G(4)K; then, it was site-specifically connected to EpCAM-targeted nanobody NB4. The in vitro characteristics of [Tc-99m]Tc-NB4 were investigated in HT-29 (EpCAM positive) and HL-60 (EpCAM negative) cells, while the in vivo studies were performed using small-animal SPECT/CT in the subcutaneous tumor models and the lymph node metastasis model to verify the specific targeting capacity as well as the potential applications of [Tc-99m]Tc-NB4. Results [Tc-99m]Tc-NB4 displayed a high EpCAM specificity both in vitro and in vivo. SPECT/CT imaging revealed that [Tc-99m]Tc-NB4 was cleared rapidly from the blood and normal organs except for the kidneys, and HT-29 tumors were clearly visualized in contrast with HL-60 tumors. The uptake value of [Tc-99m]Tc-NB4 in HT-29 tumors was increased continuously from 3.77 +/- 0.39%ID/g at 0.5 h to 5.53 +/- 0.82%ID/g at 12 h after injection. Moreover, the [Tc-99m]Tc-NB4 SPECT/CT could clearly image tumor-draining lymph nodes. Conclusion [Tc-99m]Tc-NB4 is a broad-spectrum, specific, and sensitive SPECT radiotracer for the noninvasive imaging of EpCAM expression in the epithelium-derived cancer and revealed a great potential for the clinical translation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available